| 1 |
30024740 | Multiplexed Quantitative MALDI MS Approach for Assessing Activity and Inhibition of Protein Kinases Based on Postenrichment Dephosphorylation of Phosphopeptides by Metal-Organic Framework-Templated Porous CeO2. | 2018 Aug 21 |
1 |
| 2 |
27087366 | Conformational Selection and Induced Fit Mechanisms in the Binding of an Anticancer Drug to the c-Src Kinase. | 2016 Apr 18 |
1 |
| 3 |
27480221 | Imatinib binding to human c-Src is coupled to inter-domain allostery and suggests a novel kinase inhibition strategy. | 2016 Aug 2 |
4 |
| 4 |
23146907 | Ableson kinases negatively regulate invadopodia function and invasion in head and neck squamous cell carcinoma by inhibiting an HB-EGF autocrine loop. | 2013 Oct |
1 |
| 5 |
23462796 | Imatinib mesilate-induced phosphatidylinositol 3-kinase signalling and improved survival in insulin-producing cells: role of Src homology 2-containing inositol 5'-phosphatase interaction with c-Abl. | 2013 Jun |
1 |
| 6 |
24106839 | Conformation-selective inhibitors reveal differences in the activation and phosphate-binding loops of the tyrosine kinases Abl and Src. | 2013 Dec 20 |
2 |
| 7 |
22089930 | Enhanced ABL-inhibitor-induced MAPK-activation in T315I-BCR-ABL-expressing cells: a potential mechanism of altered leukemogenicity. | 2012 Feb |
1 |
| 8 |
22280319 | The different flexibility of c-Src and c-Abl kinases regulates the accessibility of a druggable inactive conformation. | 2012 Feb 8 |
1 |
| 9 |
19714578 | New insights into small-molecule inhibitors of Bcr-Abl. | 2011 Jan |
2 |
| 10 |
20717963 | Bcr-Abl-induced tyrosine phosphorylation of Emi1 to stabilize Skp2 protein via inhibition of ubiquitination in chronic myeloid leukemia cells. | 2011 Feb |
1 |
| 11 |
21523440 | Backbone assignment of the tyrosine kinase Src catalytic domain in complex with imatinib. | 2011 Oct |
2 |
| 12 |
21760961 | Aberrant DNA methylation is associated with disease progression, resistance to imatinib and shortened survival in chronic myelogenous leukemia. | 2011 |
1 |
| 13 |
21804629 | Identification of e6a2 BCR-ABL fusion in a Philadelphia-positive CML with marked basophilia: implications for treatment strategy. | 2011 Jun |
4 |
| 14 |
20072835 | Bosutinib. | 2010 |
1 |
| 15 |
20200154 | Molecular dynamics simulations show that conformational selection governs the binding preferences of imatinib for several tyrosine kinases. | 2010 Apr 30 |
3 |
| 16 |
20445575 | Synergistic activity of the Src/Abl inhibitor bosutinib in combination with imatinib. | 2010 Jun |
1 |
| 17 |
20451394 | Dual Src and Abl inhibitors target wild type Abl and the AblT315I Imatinib-resistant mutant with different mechanisms. | 2010 Jun 1 |
2 |
| 18 |
19347730 | Activity of FB2, a novel dual Abl/Src tyrosine kinase inhibitor, against imatinib-resistant chronic myeloid leukemia in vivo and in vitro. | 2009 Mar |
1 |
| 19 |
19394692 | ZD6474 inhibits Src kinase leading to apoptosis of imatinib-resistant K562 cells. | 2009 Nov |
2 |
| 20 |
19417561 | Cas-L was overexpressed in imatinib-resistant gastrointestinal stromal tumor cells. | 2009 Apr |
2 |
| 21 |
19484755 | Flow cytometric determination of Src phosphorylation in pediatric patients treated with dasatinib. | 2009 Dec |
1 |
| 22 |
19602594 | Kinome profiling of chondrosarcoma reveals SRC-pathway activity and dasatinib as option for treatment. | 2009 Aug 1 |
1 |
| 23 |
17584806 | Imatinib mesylate inhibits in vitro and ex vivo biological responses related to vascular occlusion in giant cell arteritis. | 2008 Nov |
1 |
| 24 |
17914733 | Initial testing of dasatinib by the pediatric preclinical testing program. | 2008 Jun |
1 |
| 25 |
18338755 | Overcoming imatinib resistance using Src inhibitor CGP76030, Abl inhibitor nilotinib and Abl/Lyn inhibitor INNO-406 in newly established K562 variants with BCR-ABL gene amplification. | 2008 Jun 1 |
1 |
| 26 |
18619726 | Dasatinib exerts an immunosuppressive effect on CD8+ T cells specific for viral and leukemia antigens. | 2008 Oct |
2 |
| 27 |
18940662 | Small molecule recognition of c-Src via the Imatinib-binding conformation. | 2008 Oct 20 |
7 |
| 28 |
19047139 | Effects of dasatinib on SRC kinase activity and downstream intracellular signaling in primitive chronic myelogenous leukemia hematopoietic cells. | 2008 Dec 1 |
1 |
| 29 |
17292737 | Resistance to targeted therapy in chronic myelogenous leukemia. | 2007 Jan |
1 |
| 30 |
17348685 | Vascular endothelial growth factor receptor-3 activity is modulated by its association with caveolin-1 on endothelial membrane. | 2007 Apr 3 |
2 |
| 31 |
17355866 | c-Src binds to the cancer drug imatinib with an inactive Abl/c-Kit conformation and a distributed thermodynamic penalty. | 2007 Mar |
14 |
| 32 |
17513418 | c-Abl tyrosine kinase and inhibition by the cancer drug imatinib (Gleevec/STI-571). | 2007 Jun |
1 |
| 33 |
18159983 | Study of the interaction surface for the c-Src-imatinib complex by a molecular dicing technique. | 2007 Jul-Sep |
3 |
| 34 |
16542059 | Dasatinib: BMS 354825. | 2006 |
1 |
| 35 |
16640460 | A Src-like inactive conformation in the abl tyrosine kinase domain. | 2006 May |
1 |
| 36 |
15601623 | Two different pathways link G-protein-coupled receptors with tyrosine kinases for the modulation of growth and survival in human hematopoietic progenitor cells. | 2005 Apr |
1 |
| 37 |
15705718 | Comparative analysis of two clinically active BCR-ABL kinase inhibitors reveals the role of conformation-specific binding in resistance. | 2005 Mar 1 |
1 |
| 38 |
16105974 | NS-187, a potent and selective dual Bcr-Abl/Lyn tyrosine kinase inhibitor, is a novel agent for imatinib-resistant leukemia. | 2005 Dec 1 |
2 |
| 39 |
16179913 | Dual tyrosine kinase inhibitors in chronic myeloid leukemia. | 2005 Nov |
2 |
| 40 |
16203792 | Combined Abl inhibitor therapy for minimizing drug resistance in chronic myeloid leukemia: Src/Abl inhibitors are compatible with imatinib. | 2005 Oct 1 |
4 |
| 41 |
15201856 | Efficacy of dual-specific Bcr-Abl and Src-family kinase inhibitors in cells sensitive and resistant to imatinib mesylate. | 2004 Aug |
1 |
| 42 |
20641266 | [18F]-N-(2-Chloro-6-methylphenyl)-2-(6-(4-(2-fluoroethyl)piperazin-1-yl)-2-methylpyrimidin-4-ylamino)thiazole-5-carboxamide | 2004 |
1 |
| 43 |
12393636 | Dual-specific Src and Abl kinase inhibitors, PP1 and CGP76030, inhibit growth and survival of cells expressing imatinib mesylate-resistant Bcr-Abl kinases. | 2003 Jan 15 |
2 |
| 44 |
12654251 | Structural basis for the autoinhibition of c-Abl tyrosine kinase. | 2003 Mar 21 |
3 |